Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
1.4000 x 51 1.9500 x 3
Post-market by (Cboe BZX)
1.8500 +0.0500 (+2.78%) 04/17/25 [NASDAQ]
1.4000 x 51 1.9500 x 3
Post-market 1.8500 unch (unch) 16:00 ET
News & Headlines for Thu, Apr 17th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference GlobeNewswire - Thu Mar 20, 7:00AM CDT

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update GlobeNewswire - Thu Mar 6, 7:00AM CST

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics to Participate in March Investor Conferences GlobeNewswire - Thu Feb 20, 7:00AM CST

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis GlobeNewswire - Wed Feb 19, 7:00AM CST

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo GlobeNewswire - Mon Jan 6, 6:30AM CST

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor GlobeNewswire - Mon Dec 23, 2024

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Thu Nov 7, 2024

VYNE : 1.8500 (+2.49%)
VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis Spotlight Growth - Wed Apr 19, 2023

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development

VYNE : 1.8500 (+2.49%)
Wall Street - NYSE Full View
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus Barchart - Tue Jan 10, 2023

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

MSFT : 367.78 (-1.03%)
GOOGL : 151.22 (-1.38%)
NVDA : 101.43 (-2.93%)
AAPL : 196.93 (+1.37%)
VYNE : 1.8500 (+2.49%)
FRO : 15.44 (+4.54%)
OSH : 39.00 (+0.08%)
WWW : 10.79 (+2.37%)
ESH23 : 3,957.05s (-0.09%)
BLI : 1.2000 (-5.88%)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Globe Newswire - Wed Aug 10, 2022

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 1.8500 (+2.49%)

Barchart Exclusives

Should You Buy Tesla Stock Before April 22? Barchart - 1 hour ago
The electric vehicle maker is scheduled to report first-quarter results next week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro
Wed, Apr 23, 2025 5:00 PM UTC
Reserve Your Spot